| The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues S Hogarth, G Javitt, D Melzer Annu. Rev. Genomics Hum. Genet. 9 (1), 161-182, 2008 | 363 | 2008 |
| Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities F Becker, CG Van El, D Ibarreta, E Zika, S Hogarth, P Borry, ... European journal of human genetics 19 (1), S6-S44, 2011 | 123 | 2011 |
| Reflections on the cost of" low-cost" whole genome sequencing: framing the health policy debate T Caulfield, J Evans, A McGuire, C McCabe, T Bubela, R Cook-Deegan, ... PLoS biology 11 (11), e1001699, 2013 | 90 | 2013 |
| Valley of the unicorns: Consumer genomics, venture capital and digital disruption S Hogarth New Genetics and Society 36 (3), 250-272, 2017 | 74 | 2017 |
| Negotiating the boundary between medicine and consumer culture: Online marketing of nutrigenetic tests PM Saukko, M Reed, N Britten, S Hogarth Social science & medicine 70 (5), 744-753, 2010 | 71 | 2010 |
| Genetic tests for common diseases: new insights, old concerns D Melzer, S Hogarth, K Liddell, T Ling, S Sanderson, RL Zimmern Bmj 336 (7644), 590-593, 2008 | 69 | 2008 |
| A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA S Hogarth, MM Hopkins, V Rodriguez Sociology of health & illness 34 (2), 234-250, 2012 | 59 | 2012 |
| A market in the making: the past, present and future of direct-to-consumer genomics S Hogarth, P Saukko New Genetics and Society 36 (3), 197-208, 2017 | 57 | 2017 |
| The future of direct-to-consumer clinical genetic tests FW Frueh, HT Greely, RC Green, S Hogarth, S Siegel Nature Reviews Genetics 12 (7), 511-515, 2011 | 51 | 2011 |
| Half a century of Wilson & Jungner: reflections on the governance of population screening S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ... Wellcome Open Research 5, 158, 2020 | 34 | 2020 |
| Regenerative medicine in Europe: global competition and innovation governance S Hogarth, B Salter Regenerative Medicine 5 (6), 971-985, 2010 | 33 | 2010 |
| Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics S Hogarth Social Science & Medicine 131, 255-262, 2015 | 28 | 2015 |
| Myths, misconceptions and myopia: searching for clarity in the debate about the regulation of consumer genetics S Hogarth Public Health Genomics 13 (5), 322-326, 2010 | 24 | 2010 |
| Closing the gaps: enhancing the regulation of genetic tests using responsive regulation S Hogarth, K Liddell, T Ling, S Sanderson Food & Drug LJ 62, 831, 2007 | 24 | 2007 |
| The IVD Directive and genetic testing: problems and proposals. A briefing presented to the 20th meeting of Competent Authorities S Hogarth, D Melzer Cambridge, UK: Cambridge Univ, 2007 | 21 | 2007 |
| The golden narrative in British medicine: Dialogue and discourse in clinical practice S Hogarth, L Marks Narrative-Based Medicine, 1998 | 21 | 1998 |
| Health Canada needs to act on laboratory-developed diagnostics K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth CMAJ 191 (39), E1067-E1069, 2019 | 17 | 2019 |
| Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States S Hogarth Innovation: The European Journal of Social Science Research 25 (4), 441-460, 2012 | 16 | 2012 |
| GRAIL-Galleri: why the special treatment? C Turnbull, N Wald, R Sullivan, P Pharoah, RS Houlston, A Aggarwal, ... The Lancet 403 (10425), 431-432, 2024 | 14 | 2024 |
| Biomarker patents for diagnostics: problem or solution? MM Hopkins, S Hogarth Nature biotechnology 30 (6), 498-500, 2012 | 14 | 2012 |
